VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Symmans on Moon Shots Program for Patients With TNBC

William F. Symmans, MB, ChB
Published: Friday, Mar 11, 2016



William F. Symmans, MB, ChB, Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, discusses the institution's Moon Shots program for patients with triple-negative breast cancer (TNBC).

Within the program, researchers obtain biopsies of patients prior to their treatment, and are randomized to receive the results of a genomic test designed to predict response to chemotherapy. The results will impact whether patients receive the second half of weekly paclitaxel or an experimental therapy.

The objective of the program is to be able to conduct clinical trials of new treatments in the patient setting, where it is least likely a complete response will be reported, Symmans explains.

<<< View more from the 33rd Annual Miami Breast Cancer Conference



William F. Symmans, MB, ChB, Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, discusses the institution's Moon Shots program for patients with triple-negative breast cancer (TNBC).

Within the program, researchers obtain biopsies of patients prior to their treatment, and are randomized to receive the results of a genomic test designed to predict response to chemotherapy. The results will impact whether patients receive the second half of weekly paclitaxel or an experimental therapy.

The objective of the program is to be able to conduct clinical trials of new treatments in the patient setting, where it is least likely a complete response will be reported, Symmans explains.

<<< View more from the 33rd Annual Miami Breast Cancer Conference




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x